The FDA approved three new indications for canakinumab (Ilaris, Novartis). The new indications are for rare and serious autoinflammatory diseases in adult and pediatric patients:
• tumor necrosis factor receptor–associated periodic syndrome (TRAPS);
• hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD); and
• familial Mediterranean fever.
All three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as